SAVE trial
Last reviewed 01/2018
2231 patients with asymptomatic left ventricular dysfunction (ejection fraction <= 40%) were randomised to:
- oral captopril
- placebo
Randomisation to drug or placebo took place 3-16 days post-MI (mean 11 days).
The SAVE trial demonstrated that:
- captopril reduced mortality from all causes (20% vs. 25%)
- captopril reduced mortality attributed to cardiovascular events (21% reduction in risk)
The investigators concluded that long-term therapy with captopril is indicated in patients who have left ventricular dysfunction post-myocardial infarction.
Reference:
- (1) Pfeffer, MA. et al. (1992). Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 327(10), 669-77.